How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

559 results for

Malaria Chemoprophylaxis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Chemoprophylaxis with sporozoite immunization in P. knowlesi rhesus monkeys confers protection and elicits sporozoite-specific memory T cells in the liver. (PubMed)

Chemoprophylaxis with sporozoite immunization in P. knowlesi rhesus monkeys confers protection and elicits sporozoite-specific memory T cells in the liver. Whole malaria sporozoite vaccine regimens are promising new strategies, and some candidates have demonstrated high rates of durable clinical protection associated with memory T cell responses. Little is known about the anatomical distribution of memory T cells following whole sporozoite vaccines, and immunization of nonhuman primates can (...) be used as a relevant model for humans. We conducted a chemoprophylaxis with sporozoite (CPS) immunization in P. knowlesi rhesus monkeys and challenged via mosquito bites. Half of CPS immunized animals developed complete protection, with a marked delay in parasitemia demonstrated in the other half. Antibody responses to whole sporozoites, CSP, and AMA1, but not CelTOS were detected. Peripheral blood T cell responses to whole sporozoites, but not CSP and AMA1 peptides were observed. Unlike peripheral

Full Text available with Trip Pro

2017 PLoS ONE

22. Systematic review: Cochrane Review highlights the need for more targeted research on the tolerability of malaria chemoprophylaxis in travellers

Systematic review: Cochrane Review highlights the need for more targeted research on the tolerability of malaria chemoprophylaxis in travellers Cochrane Review highlights the need for more targeted research on the tolerability of malaria chemoprophylaxis in travellers | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cochrane Review highlights the need for more targeted research on the tolerability of malaria chemoprophylaxis

Full Text available with Trip Pro

2010 Evidence-Based Medicine (Requires free registration)

23. Blood schizonticidal activity and safety of tafenoquine when administered as chemoprophylaxis to healthy, non-immune participants followed by blood stage Plasmodium falciparum challenge: A randomized, double-blinded, placebo-controlled Phase 1b study. (PubMed)

Blood schizonticidal activity and safety of tafenoquine when administered as chemoprophylaxis to healthy, non-immune participants followed by blood stage Plasmodium falciparum challenge: A randomized, double-blinded, placebo-controlled Phase 1b study. Tafenoquine was recently approved as a chemoprophylaxis for malaria (all species). Its activity against liver and blood stages has been separately characterized in animals but not in humans.In this randomized, double-blinded, placebo-controlled (...) study, 16 malaria naïve, G6PD-normal participants aged 20-42 years received tafenoquine chemoprophylaxis prior to challenge with blood stage P. falciparum. Participants were randomly assigned to either tafenoquine (n=12) or placebo (n=4) and took blinded study medication (single 200 mg dose) on days 1, 2, 3 and 10, followed by intravenous inoculation with ~2,800 P.falciparum parasitized erythrocytes on day 13. The primary endpoint was the number of participants requiring rescue treatment

2018 Clinical Infectious Diseases Controlled trial quality: predicted high

24. DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria

DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. DSM265 Chemoprophylaxis of Plasmodium (...) post-inoculum (daily) ] Blood samples will be taken for assessment of malaria parasitemia by thick blood smear (TBS) daily on Days: D6 to D28 or early termination Secondary Outcome Measures : Number of Participants with Adverse Events as a Measure of Safety & tolerability of DSM265 [ Time Frame: From first dose (Day -1 in Cohort 1a, Day -7 in Cohort 2 and Day -X in Cohort 3) to Day 60 post-inoculum ] Safety & tolerability of DSM265 for causal and suppressive chemoprophylaxis in non-immune healthy

2015 Clinical Trials

25. Malaria Chemoprophylaxis and Self-Reported Impact on Ability to Work: Mefloquine Versus Doxycycline. (PubMed)

Malaria Chemoprophylaxis and Self-Reported Impact on Ability to Work: Mefloquine Versus Doxycycline. It is well known that both mefloquine and doxycycline are commonly associated with adverse effects when taken for malaria chemoprophylaxis. However, the relative impact of these on travelers' ability to work is not so well understood. The aim of this study was to identify which drug has a lesser impact on the ability to work as measured by self-reported severity of adverse effects via (...) were common in those that responded and, while the true background rate of adverse effects (off any medication) is unknown, doxycycline had a significantly increased rate compared with mefloquine and was associated with a greater occupational impact. Therefore, this study supports the view that, for organizations which provide malaria chemoprophylaxis to employees free of charge, mefloquine should be the first-choice antimalarial drug where the only alternative is doxycycline.© 2015 Crown copyright

Full Text available with Trip Pro

2015 Journal of Travel Medicine

26. Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Trial to Determine Safety and Development of Protective Efficacy After Exposure to Only Pre-erythrocytic Stages of Plasmodium Falciparum

called chemoprophylaxis with sporozoites (CPS) or infection treatment vaccination (ITV), can provide high level, long term protection against homologous controlled human malaria infection (CHMI). The Sanaria PfSPZ chemoprophylaxis vaccination (PfSPZ CVac) approach duplicates this with an injectable SPZ regimen. In both approaches, whether mosquitoes or syringes are used for SPZ administration, when chloroquine is used as the chemoprophylactic agent, transient, limited, asexual erythrocytic stage (...) the abnormality is not clinically significant . BMI < 17 or BMI > 35 Anticipated use during the study period, or use within the following periods prior to enrollment: Investigational malaria vaccine within the last five years Malaria chemoprophylaxis within 6 months Chronic systemic immunosuppressive medications (>14 days) within 6 months (e.g.cytotoxic medications, oral/parental corticosteroids >0.5 mg/kg/day prednisone or equivalent). Corticosteroid nasal spray for allergic rhinitis and topical

2017 Clinical Trials

27. Deaths and parasuicides associated with mefloquine chemoprophylaxis: A systematic review. (PubMed)

Deaths and parasuicides associated with mefloquine chemoprophylaxis: A systematic review. Mefloquine is recommended in international health guidelines for preventing malaria in travellers. Reports of psychosis and suicide are often alluded to but are not clearly established.We carried out a systematic review of the literature to identify and critically appraise any reported death or parasuicide associated with mefloquine prophylaxis. We developed a comprehensive search that included

Full Text available with Trip Pro

2017 Travel medicine and infectious disease

28. Pharmaceutical interactions between antiretroviral and antimalarial drugs used in chemoprophylaxis. (PubMed)

Pharmaceutical interactions between antiretroviral and antimalarial drugs used in chemoprophylaxis. Human immunodeficiency virus (HIV) is the causative agent of the Acquired Immunodeficiency Syndrome (AIDS). The pandemic is believed to have originated within the Northern Congo basin covering large parts of the Democratic Republic of Congo, the Republic of Congo, the Central African Republic, Cameroon and Gabon. Although over decades, HIV-1 has spread throughout the World leaving no country (...) unaffected, sub-Saharan Africa remains the region with more than 80% of all infected individuals. The HIV-2 epidemic has largely remained restricted to West Africa along the Upper Guinean forests. Co-incident with these regions of highest HIV distribution is a part of the malaria belt and therefore, co-infections are common. In this review we carve out the consequences of HIV transmission prevention and synchronous malaria prophylaxis during occupational or leisure travelling activities within this World

2017 Acta Tropica

29. Doxycycline for Malaria Chemoprophylaxis and Treatment: Report from the CDC Expert Meeting on Malaria Chemoprophylaxis. (PubMed)

Doxycycline for Malaria Chemoprophylaxis and Treatment: Report from the CDC Expert Meeting on Malaria Chemoprophylaxis. Doxycycline, a synthetically derived tetracycline, is a partially efficacious causal prophylactic (liver stage of Plasmodium) drug and a slow acting blood schizontocidal agent highly effective for the prevention of malaria. When used in conjunction with a fast acting schizontocidal agent, it is also highly effective for malaria treatment. Doxycycline is especially useful (...) as a prophylaxis in areas with chloroquine and multidrug-resistant Plasmodium falciparum malaria. Although not recommended for pregnant women and children < 8 years of age, severe adverse events are rarely reported for doxycycline. This report examines the evidence behind current recommendations for the use of doxycycline for malaria and summarizes the available literature on its safety and tolerability.

Full Text available with Trip Pro

2011 American Journal of Tropical Medicine & Hygiene

30. Severity of imported malaria: protective effect of taking malaria chemoprophylaxis. (PubMed)

Severity of imported malaria: protective effect of taking malaria chemoprophylaxis. Although chemoprophylaxis remains an important strategy for preventing malaria in travellers, its effectiveness may be compromised by lack of adherence. Inappropriate use of chemoprophylaxis is likely to increase the risk of acquiring malaria, but may probably also worsen the severity of imported cases. The aim of this study was to assess the impact of use of malaria chemoprophylaxis on clinical features (...) and outcome of imported malaria.Demographic, clinical and laboratory data of patients included in the Rotterdam Malaria Cohort between 1998 and 2011 were systematically collected and analysed. Patients were classified as self-reported compliant or non-compliant users or as non-users of chemoprophylaxis. Severe malaria was defined using the 2010 WHO criteria.Details on chemoprophylaxis were available for 559 of the 604 patients, of which 64.6% were non-users, 17.9% were inadequate users and 17.5% reported

Full Text available with Trip Pro

2013 Malaria journal

31. Does public subsidy of the cost of malaria chemoprophylaxis reduce imported malaria? A comparative policy analysis. (PubMed)

Does public subsidy of the cost of malaria chemoprophylaxis reduce imported malaria? A comparative policy analysis. Chemoprophylaxis is recommended for at-risk travellers visiting malaria endemic regions. The majority of travellers with imported malaria have not used this, and travellers visiting friends and relatives have the largest burden of malaria and the lowest compliance to chemoprophylaxis. In 1995, the UK's Department of Health (DH) implemented a policy to make travellers fully (...) responsible for the cost when purchasing chemoprophylaxis. This policy was not implemented in three Primary Care Trusts (PCTs) in London due to concern about the potential increase of imported malaria in their residents, and they maintained the public subsidy. An impact evaluation of the policy change was undertaken to determine if the continued subsidy reduced the incidence of imported malaria in one of the boroughs where the subsidy was maintained when compared to a borough where no subsidy

Full Text available with Trip Pro

2013 Malaria journal

32. Malaria knowledge and utilization of chemoprophylaxis in the UK population and in UK passengers departing to malaria-endemic areas. (PubMed)

Malaria knowledge and utilization of chemoprophylaxis in the UK population and in UK passengers departing to malaria-endemic areas. The burden of imported malaria is predominantly in travellers visiting friends and relatives (VFR) in sub-Saharan Africa. The failure of this group to use chemoprophylaxis is recognized as the most important risk factor for the high incidence of disease. Understanding the reasons for failure to follow national recommendations may relate to knowledge, risk (...) knowledge among the UK population (score 58.6) was significantly lower than that of individuals who had previously travelled or were travelling (63.8 and 70.7 respectively). Malaria knowledge was similar in individuals who had and had not sought pre-travel advice and travellers using and not using chemoprophylaxis for their journey. Leisure travellers to Ghana and Nigeria were predominantly VFRs (74%), whilst 66% of travellers to Kenya were tourists. Despite similar high knowledge scores and perceived

Full Text available with Trip Pro

2013 Malaria journal

33. Low uptake of preventive interventions among malaria cases in Swaziland: towards malaria elimination (PubMed)

Low uptake of preventive interventions among malaria cases in Swaziland: towards malaria elimination Settings: Swaziland is striving to achieve sustainable malaria elimination. Three preventive interventions are vital for reaching this goal: 1) effective household utilisation of long-lasting insecticide nets (LLINs), 2) indoor residual spraying (IRS), and 3) provision of chemoprophylaxis for those travelling to malaria-endemic areas. Objectives: To assess the uptake of preventive intervention (...) travellers to areas at high malaria risk, 59 (4%) used any form of malaria prevention, including chemoprophylaxis. Conclusion: The uptake of all three key malaria prevention interventions is low, and could threaten the progress made thus far toward malaria elimination. Efforts to improve this situation, including qualitative research to understand the reasons for low uptake, are urgently needed.

Full Text available with Trip Pro

2018 Public health action

34. Chemoprophylaxis and intermittent treatment for preventing malaria in children. (PubMed)

Chemoprophylaxis and intermittent treatment for preventing malaria in children. Malaria causes repeated illness in children living in endemic areas. Policies of giving antimalarial drugs at regular intervals (prophylaxis or intermittent treatment) are being considered for preschool children.To evaluate prophylaxis and intermittent treatment with antimalarial drugs to prevent malaria in young children living in malaria-endemic areas.We searched the Cochrane Infectious Diseases Group Specialized (...) Register (August 2007), CENTRAL (The Cochrane Library 2007, Issue 3), MEDLINE (1966 to August 2007), EMBASE (1974 to August 2007), LILACS (1982 to August 2007), mRCT (February 2007), and reference lists of identified trials. We also contacted researchers.Individually randomized and cluster-randomized controlled trials comparing antimalarial drugs given at regular intervals (prophylaxis or intermittent treatment) with placebo or no drug in children aged one month to six years or less living in a malaria

Full Text available with Trip Pro

2008 Cochrane

35. Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

has been or will be exposed to an investigational or a non-investigational vaccine/product. Seropositive for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV). Documented HIV-positive subject. Previous vaccination against malaria. History of malaria chemoprophylaxis within 60 days prior to vaccination. Any history of malaria (for the vaccine groups). Planned travel to malaria endemic areas during the study period. History of splenectomy. Any confirmed or suspected immunosuppressive (...) Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting

2017 Clinical Trials

36. Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis

, healthy, malaria naïve volunteers will receive three injections by Direct Venous Inoculation (DVI) of either placebo (n = 10), 51,200 PfSPZ Challenge (NF54) (n = 10), or 150,000 PfSPZ Challenge (NF54) (n = 10) under chemoprophylaxis with A/P at 4 week intervals. The placebo will be NaCl 0.9%. Ten weeks after the last dose of PfSPZ Challenge (NF54) for immunization, volunteers will undergo first CHMI and followed until asexual blood stage parasitemia, detected by quantitative real time PCR (qPCR (...) chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals Drug: atovaquone/proguanil 250mg/100mg (A/P) Combination drug for chemo-prophylaxis or treatment of malaria Other Name: Malarone Biological: PfSPZ Challenge (NF54) cryo-preserved Plasmodium falciparum sporozoites injected by venous inoculation Experimental: 150,000 PfSPZ Three injections of 150,000 PfSPZ Challenge (P. falciparum strain: NF54) under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals

2016 Clinical Trials

37. Relapsing malaria: two cases of malaria presenting 8 months after return from Africa despite adherence to antimalarial chemoprophylaxis (PubMed)

Relapsing malaria: two cases of malaria presenting 8 months after return from Africa despite adherence to antimalarial chemoprophylaxis 23265223 2013 12 17 2018 11 13 1478-5242 62 603 2012 Oct The British journal of general practice : the journal of the Royal College of General Practitioners Br J Gen Pract Relapsing malaria: two cases of malaria presenting 8 months after return from Africa despite adherence to antimalarial chemoprophylaxis. 555-6 10.3399/bjgp12X657017 Morgan Gemma S GS NHS (...) Bristol, Marlborough Street, Bristol, UK. gemma.morgan@nhs.net Chiodini Peter P Evans Mark M eng Case Reports Journal Article England Br J Gen Pract 9005323 0960-1643 0 Antimalarials 0 Drug Combinations 0 atovaquone, proguanil drug combination S61K3P7B2V Proguanil Y883P1Z2LT Atovaquone IM Adolescent Africa Antimalarials therapeutic use Atovaquone therapeutic use Delayed Diagnosis Drug Combinations Humans Malaria diagnosis parasitology prevention & control Male Medication Adherence Plasmodium ovale

Full Text available with Trip Pro

2012 The British Journal of General Practice

38. The efficacy of malaria chemoprophylaxis

The efficacy of malaria chemoprophylaxis The efficacy of malaria chemoprophylaxis The efficacy of malaria chemoprophylaxis Saridi M, Vasiliki P, Saroglou G CRD summary The authors concluded that atovaquone/proguanil, tafenoquine, primaquine were the most effective regimens for malaria chemoprophylaxis, but tafenoquine and primaquine should not be prescribed to individuals with G6PD deficiency. Given the limitations of the review data and concerns about the methodology and reporting (...) , Saroglou G. The efficacy of malaria chemoprophylaxis. Health Science Journal 2008; 2(1): 3-14 Indexing Status Subject indexing assigned by CRD MeSH Aminoquinolines /therapeutic use; Antimalarials /therapeutic use; Atovaquone /therapeutic use; Chemoprevention; Communicable Disease Control; Malaria /prevention & Primaquine /therapeutic use; control AccessionNumber 12008105102 Date bibliographic record published 03/02/2009 Date abstract record published 13/01/2010 Record Status This is a critical abstract

2008 DARE.

39. Reimbursement of malaria chemoprophylaxis for travellers from Europe to Sub-Saharan Africa: cost-effectiveness analysis from the perspective of the French national health insurance system

Reimbursement of malaria chemoprophylaxis for travellers from Europe to Sub-Saharan Africa: cost-effectiveness analysis from the perspective of the French national health insurance system Reimbursement of malaria chemoprophylaxis for travellers from Europe to Sub-Saharan Africa: cost-effectiveness analysis from the perspective of the French national health insurance system Reimbursement of malaria chemoprophylaxis for travellers from Europe to Sub-Saharan Africa: cost-effectiveness analysis (...) compared the cost-effectiveness of reimbursing malaria chemoprophylaxis at a rate of 65% against the usual strategy of no reimbursement, for French residents who occasionally travelled to Sub-Saharan Africa. The authors concluded that 65% reimbursement was a cost-effective strategy from the perspective of the French national health insurance system. The analysis had several limitations and the reporting, especially for the effectiveness data, was insufficient. The authors’ conclusions should be treated

2008 NHS Economic Evaluation Database.

40. Summary of recommendations for the diagnosis and treatment of malaria by the Committee to Advise on Tropical Medicine and Travel (CATMAT)

of respected authorities on the basis of clinical experience, descriptive studies, or reports of expert committees Malaria Diagnosis Malaria could be the reason for any etiologically unidentified fever that develops while a traveller is in a malaria-endemic area or up to one year after leaving, irrespective of chemoprophylaxis use . If a fever occurs during this time, the traveller should seek medical attention immediately and tell the health care provider about his/her travel history. Particular attention (...) as malaria chemoprophylaxis); doxycycline (unless used as malaria chemoprophylaxis; contraindications: pregnancy, breastfeeding, age < 8 years) ; clindamycin (only if the patient is unable to take doxycycline or atovaquone-proquanil). Table 2 identifies the common antimalarial drugs and their indications. Table 2: Recommendations for common antimalarial drugs Indication Additional notes Intravenous artesunate First-line treatment of severe falciparum malaria or if intravenous quinine is not tolerated

2014 CPG Infobase

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>